FindTrial
Sign In

Establish a pharmaceutical care mode for therapeutic drug monitoring of voriconazole and evaluate its effectiveness and economics

Establish a pharmaceutical care mode for therapeutic drug monitoring of voriconazole and evaluate its effectiveness and economics

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000030653
Enrollment
Unknown
Registered
2020-03-08
Start date
2020-03-01
Completion date
Unknown
Last updated
2020-03-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

invasive fungal disease

Interventions

experimental group:pharmaceutical care
Control group:Traditional model

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
12 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Patients with invasive fungal disease; 2. Treated with voriconazole; 3. Liver enzymes and bilirubin were measured before vancomycin use.

Exclusion criteria

Exclusion criteria: 1. Pregnant and nursing women 2. Fungal infection of lower urinary tract 3. Combination drugs with significant hepatotoxicity (e.g. isoniazide, pyrazinamide).

Design outcomes

Primary

MeasureTime frame
Clinical efficiency;Incidence of voriconazole related hepatotoxicity;cost;—

Secondary

MeasureTime frame
the rate of voriconazole trough concentrations within the desired target range;—

Countries

China

Contacts

Public ContactMing Hu

West China Hospital, Sichuan University

huming@scu.edu.cn+86(028)85501387

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026